Partnering with BeiGene

Partnering with
BeiGene

We are committed to partnering with academia, biotech and pharmaceutical companies around the world to jointly discover and develop innovative products that will bring meaningful treatments to cancer patients. BeiGene’s combination of a world-class clinical development team and an experienced commercial team in China differentiates us. Our business development team is dedicated to make a positive impact in the fight against cancers.

I have the privilege to lead the talented business development team here at BeiGene as we uncover new, promising cancer treatments. We are each focused on developing those innovative therapies thoughtfully so they can be made accessible to the patients who need them as quickly as possible.

Guillaume Vignon, Ph.D.
Guillaume Vignon, Senior Vice President, Business Development

 

  • 4200+

    Employees

  • 1100+

    Clinical Team

  • 5

    Continents

 

Our Partners

Amgen
Amgen

Read more about our global strategic oncology collaboration.

Mirati Therapeutics Logo
Mirati Therapeutics

Read more about our exclusive license agreement for sitravatinib in the Asia Pacific Region.

Mei Pharma Logo
MEI

Read more about this clinical collaboration agreement.

Zymeworks logo
Zymeworks

Read more about the license and collaboration agreements. 

Ambrx
Ambrx

Read more about the license and collaboration agreements. 

BioAtla
BioAtla

Read more about the license and collaboration agreements. 

Seagen
Seagen

Read more about the license and collaboration agreements. 

Leap Therapeutics
Leap Therapeutics

Read more about our exclusive option and license agreement.

EUSA
EUSA Pharma

Read more about this exclusive development and commercialization agreement. 

Chi-Med
Chi-Med

Read more about this clinical collaboration agreement.

Assembly Biosciences
Assembly Biosciences

Read more about the license and collaboration agreements.

Bio-Thera Solutions
Bio-Thera Solutions

Read more about the license and collaboration agreements.

Singlomics
Singlomics

Read more about this exclusive license agreement.

X